Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?

Ehrenkranz, 2005, Phlorizin: a review, Diabetes Metab Res Rev, 21, 31, 10.1002/dmrr.532 Panchapakesan, 2013, Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?, PLOS ONE, 8, 10.1371/journal.pone.0054442 Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 373, 2117, 10.1056/NEJMoa1504720 Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 377, 644, 10.1056/NEJMoa1611925 Wiviott, 2019, Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 380, 347, 10.1056/NEJMoa1812389 Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920 Perkovic, 2019, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med, 380, 2295, 10.1056/NEJMoa1811744 Heerspink, 2020, Dapagliflozin in patients with chronic kidney disease, N Engl J Med, 383, 1436, 10.1056/NEJMoa2024816 2022, Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial, Nephrol Dial Transplant, 37, 1317, 10.1093/ndt/gfac040 The EMPA-KIDNEY Collaborative Group, 2023, Empagliflozin in patients with chronic kidney disease, N Engl J Med, 388, 117, 10.1056/NEJMoa2204233 2022, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials, Lancet, 400, 1788, 10.1016/S0140-6736(22)02074-8 Wheeler, 2021, A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy, Kidney Int, 100, 215, 10.1016/j.kint.2021.03.033 Heerspink, 2020, Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study, Lancet Diabetes Endocrinol, 8, 27, 10.1016/S2213-8587(19)30384-5 Schmidt, 2021, Are the protective effects of SGLT2 inhibitors a “class-effect” or are there differences between agents?, Kidney360, 2, 881, 10.34067/KID.0000622021 Johansen, 2020, The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use sodium glucose cotransporter 2 inhibitors is now, Clin Cardiol, 43, 1376, 10.1002/clc.23508 Thomson, 2012, Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat, Am J Physiol Regul Integr Comp Physiol, 302, R75, 10.1152/ajpregu.00357.2011 Tuttle, 2021, SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation, Am J Kidney Dis, 77, 94, 10.1053/j.ajkd.2020.08.003 Lytvyn, 2022, Renal and vascular effects of combined SGLT2 and angiotensin-converting enzyme inhibition, Circulation, 146, 450, 10.1161/CIRCULATIONAHA.122.059150 Kraus, 2021, Characterization and implications of the initial estimated glomerular filtration rate “dip” upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial, Kidney Int, 99, 750, 10.1016/j.kint.2020.10.031 Adamson, 2022, Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF, Circulation, 146, 438, 10.1161/CIRCULATIONAHA.121.058910 Oshima, 2021, Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice, Kidney Int, 99, 999, 10.1016/j.kint.2020.10.042 Zhuo, 2022, SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes, Am J Kidney Dis, 79, 858, 10.1053/j.ajkd.2021.09.015 Menne, 2019, Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis, PLOS Med, 16, 10.1371/journal.pmed.1002983 Qiu, 2021, Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Diab, Vasc Dis Res, 18 Jongs, 2022, Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD, J Am Soc Nephrol, 33, 2094, 10.1681/ASN.2022030306 Lam, 2021, Real-life prescribing of SGLT2 inhibitors: how to handle the other medications, including glucose-lowering drugs and diuretics, Kidney360, 2, 742, 10.34067/KID.0000412021 Ogawa, 2016, Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors, J Diabetes Investig, 7, 135, 10.1111/jdi.12401 Cai, 2021, Dapagliflozin in patients with chronic heart failure: a systematic review and meta-analysis, Cardiol Res Pract, 2021, 10.1155/2021/6657380 Varshney, 2021, Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes, Ther Adv Drug Saf, 12, 10.1177/2042098621997703 Hall, 2017, Caution advised with dapagliflozin in the setting of male urinary tract outlet obstruction, BMJ Case Rep, 2017 Zoungas, 2021, SGLT2 inhibitors in diabetic kidney disease, Clin J Am Soc Nephrol, 16, 631, 10.2215/CJN.18881220